These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 29482551)

  • 1. Clinical significance of plasma cell-free DNA mutations in PIK3CA, AKT1, and ESR1 gene according to treatment lines in ER-positive breast cancer.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Iwase H
    Mol Cancer; 2018 Feb; 17(1):67. PubMed ID: 29482551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Iwase H
    Cancer Biomark; 2018; 22(2):345-350. PubMed ID: 29689710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
    Oncotarget; 2016 May; 7(22):32504-18. PubMed ID: 27102299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Tomiguchi M; Sueta A; Murakami K; Omoto Y; Iwase H
    Oncotarget; 2017 Aug; 8(32):52142-52155. PubMed ID: 28881720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer.
    Shibayama T; Low SK; Ono M; Kobayashi T; Kobayashi K; Fukada I; Ito Y; Ueno T; Ohno S; Nakamura Y; Takahashi S
    Breast Cancer Res Treat; 2020 Apr; 180(2):331-341. PubMed ID: 32020432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prevalence of estrogen receptor-1 mutation in advanced breast cancer: The estrogen receptor one study (EROS1).
    Najim O; Huizing M; Papadimitriou K; Trinh XB; Pauwels P; Goethals S; Zwaenepoel K; Peterson K; Weyler J; Altintas S; van Dam P; Tjalma W
    Cancer Treat Res Commun; 2019; 19():100123. PubMed ID: 30826563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.
    Guttery DS; Page K; Hills A; Woodley L; Marchese SD; Rghebi B; Hastings RK; Luo J; Pringle JH; Stebbing J; Coombes RC; Ali S; Shaw JA
    Clin Chem; 2015 Jul; 61(7):974-82. PubMed ID: 25979954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer.
    Herberts C; Murtha AJ; Fu S; Wang G; Schönlau E; Xue H; Lin D; Gleave A; Yip S; Angeles A; Hotte S; Tran B; North S; Taavitsainen S; Beja K; Vandekerkhove G; Ritch E; Warner E; Saad F; Iqbal N; Nykter M; Gleave ME; Wang Y; Annala M; Chi KN; Wyatt AW
    Eur Urol; 2020 Dec; 78(6):834-844. PubMed ID: 32451180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.
    Park J; Chang ES; Kim JY; Chelakkot C; Sung M; Song JY; Jung K; Lee JH; Choi JY; Kim NY; Lee H; Kang MR; Kwon MJ; Shin YK; Park YH; Choi YL
    Breast Cancer Res; 2024 Jan; 26(1):13. PubMed ID: 38238761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
    Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
    PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma cell-free tumor DNA, PIK3CA and TP53 mutations predicted inferior endocrine-based treatment outcome in endocrine receptor-positive metastatic breast cancer.
    Chen TW; Hsiao W; Dai MS; Lin CH; Chang DY; Chen IC; Wang MY; Chang SH; Huang SM; Cheng AL; Wu KW; Tan KT; Lu YS
    Breast Cancer Res Treat; 2023 Oct; 201(3):377-385. PubMed ID: 37344660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
    Xing Y; Lin NU; Maurer MA; Chen H; Mahvash A; Sahin A; Akcakanat A; Li Y; Abramson V; Litton J; Chavez-MacGregor M; Valero V; Piha-Paul SA; Hong D; Do KA; Tarco E; Riall D; Eterovic AK; Wulf GM; Cantley LC; Mills GB; Doyle LA; Winer E; Hortobagyi GN; Gonzalez-Angulo AM; Meric-Bernstam F
    Breast Cancer Res; 2019 Jul; 21(1):78. PubMed ID: 31277699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Insights of Pathways Resulting from Two Common PIK3CA Mutations in Breast Cancer.
    Bhat-Nakshatri P; Goswami CP; Badve S; Magnani L; Lupien M; Nakshatri H
    Cancer Res; 2016 Jul; 76(13):3989-4001. PubMed ID: 27197157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients.
    Deng L; Zhu X; Sun Y; Wang J; Zhong X; Li J; Hu M; Zheng H
    Cancer Res Treat; 2019 Jan; 51(1):128-140. PubMed ID: 29540052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen receptor mutations and splice variants determined in liquid biopsies from metastatic breast cancer patients.
    Beije N; Sieuwerts AM; Kraan J; Van NM; Onstenk W; Vitale SR; van der Vlugt-Daane M; Dirix LY; Brouwer A; Hamberg P; de Jongh FE; Jager A; Seynaeve CM; Jansen MPHM; Foekens JA; Martens JWM; Sleijfer S
    Mol Oncol; 2018 Jan; 12(1):48-57. PubMed ID: 29063679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.
    Sabine VS; Crozier C; Brookes CL; Drake C; Piper T; van de Velde CJ; Hasenburg A; Kieback DG; Markopoulos C; Dirix L; Seynaeve C; Rea DW; Bartlett JM
    J Clin Oncol; 2014 Sep; 32(27):2951-8. PubMed ID: 25071141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial.
    Chandarlapaty S; Chen D; He W; Sung P; Samoila A; You D; Bhatt T; Patel P; Voi M; Gnant M; Hortobagyi G; Baselga J; Moynahan ME
    JAMA Oncol; 2016 Oct; 2(10):1310-1315. PubMed ID: 27532364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.
    Takeshita T; Yamamoto Y; Yamamoto-Ibusuki M; Inao T; Sueta A; Fujiwara S; Omoto Y; Iwase H
    Cancer Sci; 2015 Nov; 106(11):1582-9. PubMed ID: 26353837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
    Spoerke JM; Gendreau S; Walter K; Qiu J; Wilson TR; Savage H; Aimi J; Derynck MK; Chen M; Chan IT; Amler LC; Hampton GM; Johnston S; Krop I; Schmid P; Lackner MR
    Nat Commun; 2016 May; 7():11579. PubMed ID: 27174596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.